Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 10:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–23 of 23 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Injection Site Infection Clear all
Terminated Phase 1 Interventional Results available

Ipilimumab and Local Radiation for Selected Solid Tumors

NCT01769222
View directory record Official record
Conditions
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Hepatosplenic T-cell Lymphoma, Intraocular Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Peripheral T-cell Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Colon Cancer, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Melanoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Rectal Cancer, Recurrent Small Lymphocytic Lymphoma, Refractory Hairy Cell Leukemia, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, T-cell Large Granular Lymphocyte Leukemia, Testicular Lymphoma, Waldenström Macroglobulinemia
Interventions
Ipilimumab, Radiation therapy
Biological · Radiation
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jan 23, 2024 · Synced Jul 23, 2026, 10:17 AM EDT
Completed Not applicable Interventional Results available

RAL-eve Study: Raltegravir Substitution Study

NCT00523237
View directory record Official record
Conditions
HIV Infections
Interventions
Raltegravir
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Nov 1, 2011 · Synced Jul 23, 2026, 10:17 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Simultaneous mRNA COVID-19 and IIV4 Vaccination Study

NCT05028361
View directory record Official record
Conditions
Quality of Life, Injection Site Reaction, Adverse Drug Event, Systemic Reaction
Interventions
mRNA COVID-19, IIV4, Placebo (saline)
Biological · Other
Lead sponsor
Duke University
Other
Eligibility
5 Years and older
Enrollment
348 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
3
States / cities
Baltimore, Maryland • Durham, North Carolina • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 18, 2024 · Synced Jul 23, 2026, 10:17 AM EDT
Recruiting Phase 2 Interventional

EMLA Topical Cream for Treatment of Pain in Patients Receiving Intra-Dermal Technetium 99 Injections for Lymphoscintigraphy for Skin Cancers

NCT06223659
View directory record Official record
Conditions
Cutaneous Melanoma, Merkel Cell Carcinoma, Skin Squamous Cell Carcinoma
Interventions
Eutectic Mixture of Local Anesthetics, Placebo Administration, Questionnaire Administration
Drug · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years to 99 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Jul 23, 2026, 10:17 AM EDT
Active, not recruiting Phase 1 Interventional

In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors

NCT04616248
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8, Unresectable Breast Carcinoma, Metastatic Melanoma, Unresectable Melanoma, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, Soft Tissue Sarcoma, Bone Sarcoma, Sarcoma,Soft Tissue, Sarcoma of Bone, Basal Cell Carcinoma
Interventions
Anti-CD40 Agonist Monoclonal Antibody CDX-1140, Poly ICLC, Radiation Therapy, Recombinant Flt3 Ligand, Pembrolizumab, Tocilizumab
Biological · Drug · Radiation
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Jul 23, 2026, 10:17 AM EDT
Completed Phase 1 Interventional

Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors in Pediatric Patients

NCT01169584
View directory record Official record
Conditions
Neuroblastoma, Rhabdomyosarcoma, Lymphoma, Wilm's Tumor, Ewing's Sarcoma
Interventions
Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)
Drug
Lead sponsor
Jennerex Biotherapeutics
Industry
Eligibility
2 Years to 21 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
2
States / cities
Cincinnati, Ohio • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 20, 2016 · Synced Jul 23, 2026, 10:17 AM EDT
Active, not recruiting Not applicable Interventional

Integrated Care and Treatment for Severe Infectious Diseases and Substance Use Disorders Among Hospitalized Patients

NCT05688423
View directory record Official record
Conditions
Injection Site Infection, Substance Use Disorders
Interventions
SIRI Team, Treatment as Usual
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
6
States / cities
Birmingham, Alabama • Miami, Florida • Tampa, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Jul 23, 2026, 10:17 AM EDT
Withdrawn Phase 2 Interventional

A Phase II Study of Neoadjuvant E7 TCR T Cell Immunotherapy for Borderline Resectable and Unresectable Stage I HPV-Associated Oropharyngeal Cancer

NCT04044950
View directory record Official record
Conditions
Papillomavirus Infections, Oropharyngeal Neoplasms
Interventions
E7 TCR
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 21, 2020 · Synced Jul 23, 2026, 10:17 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Simultaneous RZV and aIIV4 Vaccination

NCT05007041
View directory record Official record
Conditions
Pain, Quality of Life, Injection Site Reaction, Adverse Drug Event
Interventions
FLUAD® Quadrivalent, Fluzone® High-Dose Quadrivalent, SHINGRIX®
Biological
Lead sponsor
Duke University
Other
Eligibility
65 Years and older
Enrollment
267 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
2
States / cities
Baltimore, Maryland • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 10, 2024 · Synced Jul 23, 2026, 10:17 AM EDT
Recruiting Phase 1 Interventional

Intra-tumoral (IT) Injection of vvDD-hIL2-2-RG-1 for Metastatic Gastrointestinal and Peritoneal Tumors

NCT07001592
View directory record Official record
Conditions
Gastric Neoplasms, Esophageal Cancer, Liver Cancer, Liver Metastasis, MSS-CRC, MSS, Gastric Adenocarcinoma, Peritoneal Cancer, Peritoneal Carcinoma, Peritoneal Metastases, MSI-H, Gastric Cancer
Interventions
vvDD-hIL-2-RG-1
Biological
Lead sponsor
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Other
Eligibility
18 Years to 69 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 2, 2025 · Synced Jul 23, 2026, 10:17 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate if Long Acting Cabotegravir (CAB) and Lenacapavir (LEN) Injections Are Tolerable and Acceptable When Administered to Healthy Adults Without HIV

NCT06970223
View directory record Official record
Conditions
HIV Infections
Interventions
Cabotegravir long-acting, Lenacapavir long-acting
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Nov 27, 2025 · Synced Jul 23, 2026, 10:17 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Relative Bioavailability, Safety, and Tolerability of Single-dose Sotrovimab Injection in Adults (COSMIC)

NCT05280717
View directory record Official record
Conditions
Covid19
Interventions
sotrovimab
Biological
Lead sponsor
Vir Biotechnology, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
316 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
10
States / cities
Riverside, California • Atlantis, Florida • Edgewater, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Jul 23, 2026, 10:17 AM EDT
Completed Phase 1 Interventional

Safety Study of Modified Vaccinia Virus to Cancer

NCT00574977
View directory record Official record
Conditions
Melanoma, Breast Cancer, Head and Neck Squamous Cell Cancer, Liver Cancer, Colorectal Cancer, Pancreatic Adenocarcinoma
Interventions
Vaccinia virus (vvDD-CDSR)
Biological
Lead sponsor
David Bartlett
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 27, 2015 · Synced Jul 23, 2026, 10:17 AM EDT
Completed Phase 3 Interventional

Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment

NCT00008359
View directory record Official record
Conditions
Cancer
Interventions
caspofungin acetate, liposomal amphotericin B
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
16 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 17, 2013 · Synced Jul 23, 2026, 10:17 AM EDT
Completed Not applicable Interventional Results available

RECELL® System Combined With Meshed Autograft for Reduction of Donor Skin Harvesting in Soft Tissue Reconstruction

NCT04091672
View directory record Official record
Conditions
Full-thickness Skin Defects, Degloving Injuries, Crush Injuries, Laceration of Skin, Surgical Wound, Skin Cancer, Cellulitis, Infection, Necrotizing Fasciitis, Gun Shot Wound
Interventions
Control Intervention (Conventional Autograft), Investigational Intervention (RECELL + more widely meshed autograft)
Procedure · Device
Lead sponsor
Avita Medical
Industry
Eligibility
5 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
18
States / cities
Phoenix, Arizona • Tucson, Arizona • Orange, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2024 · Synced Jul 23, 2026, 10:17 AM EDT
Completed No phase listed Observational

HIV Infection and Tobacco Use Among Injection Drug Users in Baltimore, Maryland: A Pilot Study of Biomarkers

NCT00491335
View directory record Official record
Conditions
HIV Infections, AIDS, Lung Cancer, Tobacco Addiction, Drug Addiction
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
17 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jul 23, 2026, 10:17 AM EDT
Completed Phase 1 Interventional

Phase I Trial of mBACOD and Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in AIDS-Associated Large Cell, Immunoblastic, and Small Non-cleaved Lymphoma

NCT00000689
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin, HIV Infections
Interventions
Bleomycin sulfate, Vincristine sulfate, Doxorubicin hydrochloride, Cyclophosphamide, Methotrexate, Cytarabine, Leucovorin calcium, Sargramostim, Dexamethasone
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1991
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Jul 23, 2026, 10:17 AM EDT
Completed Not applicable Interventional Results available

Intensive Models of HCV Care for Injection Drug Users

NCT01857245
View directory record Official record
Conditions
Hepatitis C, Medication Adherence
Interventions
Intensive Models (mDOT and CGT) of HCV Care
Other
Lead sponsor
Prisma Health-Upstate
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Feb 2, 2025 · Synced Jul 23, 2026, 10:17 AM EDT
Active, not recruiting Phase 3 Interventional

Tobramycin Injection to Prevent Infection in Open Fractures

NCT04964947
View directory record Official record
Conditions
Wound Infection, Fractures, Open, Surgical Site Infection
Interventions
Tobramycin Injection
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
3
States / cities
Lexington, Kentucky • Boston, Massachusetts • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Jul 23, 2026, 10:17 AM EDT
Terminated Phase 1 Interventional

Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides

NCT02890368
View directory record Official record
Conditions
Solid Tumors, Mycosis Fungoides, Melanoma, Merkel-cell Carcinoma, Squamous Cell Carcinoma, Breast Carcinoma, Human Papillomavirus-Related Malignant Neoplasm, Soft Tissue Sarcoma
Interventions
TTI-621 Monotherapy, TTI-621 + PD-1/PD-L1 Inhibitor, TTI-621 + pegylated interferon-α2a, TTI-621 + T-Vec, TTI-621 + radiation
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
7
States / cities
Duarte, California • New York, New York • Portland, Oregon + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2023 · Synced Jul 23, 2026, 10:17 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

FLUAD® vs. Fluzone® High-Dose Study

NCT03183908
View directory record Official record
Conditions
Pain, Quality of Life, Injection Site Reaction, Side Effect of Drug, Adverse Drug Event
Interventions
FLUAD®, Fluzone® High-Dose
Biological
Lead sponsor
Duke University
Other
Eligibility
65 Years and older
Enrollment
757 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
4
States / cities
Atlanta, Georgia • Boston, Massachusetts • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2021 · Synced Jul 23, 2026, 10:17 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Topical Proparacaine Eye Drops to Improve the Experience of Patients Undergoing Intravitreal Injections

NCT02951351
View directory record Official record
Conditions
Age-related Macular Degeneration, Diabetic Macular Edema, Injection Site, Injection Site Infection, Pain, Postoperative
Interventions
Proparacaine, Conjunctival culture
Drug · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 11, 2023 · Synced Jul 23, 2026, 10:17 AM EDT
Recruiting Phase 1Phase 2 Interventional

Study to Investigate the Safety of the Transplantation of Human Glial Restricted Progenitor Cells Into Subjects With Transverse Myelitis

NCT03887273
View directory record Official record
Conditions
Transverse Myelitis
Interventions
Q-Cells
Biological
Lead sponsor
Q Therapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Jul 23, 2026, 10:17 AM EDT